Tuesday, November 15, 2011
Anavex Life Sciences Corp., of Hoboken, N.J., completed a Phase I single ascending dose trial of Anavex 2-73, the first of a new class of oral drugs being developed to treat Alzheimer's through disease modification rather than focusing on symptomatic improvement. Anavex 2-73 was well tolerated below the 55 mg to 60 mg dose with only mild adverse events in some volunteers. The company plans to begin a multiple ascending dose trial immediately.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.